MYGN – Myriad Genetics, Inc.
MYGN — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
8.91
Margin Of Safety %
Put/Call OI Ratio
0.17
EPS Next Q Diff
0.23
EPS Last/This Y
4
EPS This/Next Y
0.11
Price
3.82
Target Price
6.38
Analyst Recom
2.9
Performance Q
-12.79
Upside
-4,058.1%
Beta
1.77
Ticker: MYGN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-23 | MYGN | 4.78 | 0.46 | 999.99 | 1559 |
| 2026-04-24 | MYGN | 4.77 | 0.50 | 0.11 | 1601 |
| 2026-04-27 | MYGN | 4.84 | 0.48 | 0.10 | 1661 |
| 2026-04-28 | MYGN | 4.84 | 0.47 | 0.50 | 1706 |
| 2026-04-29 | MYGN | 4.69 | 0.47 | 5.25 | 1706 |
| 2026-04-30 | MYGN | 4.73 | 0.48 | 0.00 | 1729 |
| 2026-05-01 | MYGN | 4.8 | 0.46 | 3.19 | 1787 |
| 2026-05-04 | MYGN | 4.93 | 0.38 | 0.00 | 1738 |
| 2026-05-05 | MYGN | 5.02 | 0.35 | 0.55 | 1836 |
| 2026-05-06 | MYGN | 4.11 | 0.39 | 0.52 | 1945 |
| 2026-05-07 | MYGN | 4.09 | 0.41 | 0.02 | 2202 |
| 2026-05-08 | MYGN | 4.28 | 0.41 | 0.18 | 2212 |
| 2026-05-11 | MYGN | 4.22 | 0.36 | 0.02 | 2124 |
| 2026-05-12 | MYGN | 4.07 | 0.36 | 0.02 | 2124 |
| 2026-05-13 | MYGN | 3.73 | 0.33 | 0.09 | 2201 |
| 2026-05-14 | MYGN | 3.62 | 0.32 | 0.08 | 2219 |
| 2026-05-15 | MYGN | 3.57 | 0.30 | 0.03 | 2217 |
| 2026-05-18 | MYGN | 3.64 | 0.18 | 0.00 | 1425 |
| 2026-05-19 | MYGN | 3.54 | 0.17 | 0.00 | 1523 |
| 2026-05-20 | MYGN | 3.81 | 0.17 | 0.00 | 1525 |
| 2026-05-21 | MYGN | 3.91 | 0.17 | 0.00 | 1526 |
| 2026-05-22 | MYGN | 3.82 | 0.17 | 0.39 | 1528 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-23 | MYGN | 4.79 | -129.8 | 390.2 | 0.04 |
| 2026-04-24 | MYGN | 4.78 | -122.8 | 390.2 | 0.05 |
| 2026-04-27 | MYGN | 4.84 | -122.8 | 390.2 | 0.05 |
| 2026-04-28 | MYGN | 4.84 | -122.8 | 390.3 | 0.05 |
| 2026-04-30 | MYGN | 4.74 | -122.8 | 390.2 | 0.05 |
| 2026-05-01 | MYGN | 4.80 | -122.8 | 390.2 | 0.05 |
| 2026-05-04 | MYGN | 4.93 | -122.8 | 390.3 | 0.05 |
| 2026-05-05 | MYGN | 5.02 | -122.8 | 390.5 | 0.05 |
| 2026-05-06 | MYGN | 4.10 | -122.8 | 389.4 | 0.05 |
| 2026-05-07 | MYGN | 4.09 | -122.8 | - | 0.05 |
| 2026-05-08 | MYGN | 4.29 | -122.8 | - | 0.06 |
| 2026-05-11 | MYGN | 4.22 | -67.5 | - | 0.06 |
| 2026-05-12 | MYGN | 4.07 | -67.5 | - | 0.06 |
| 2026-05-13 | MYGN | 3.74 | -67.5 | - | 0.06 |
| 2026-05-14 | MYGN | 3.63 | -67.5 | - | 0.06 |
| 2026-05-15 | MYGN | 3.57 | -67.5 | - | 0.06 |
| 2026-05-18 | MYGN | 3.64 | -175.6 | - | 0.06 |
| 2026-05-19 | MYGN | 3.54 | -175.6 | - | 0.06 |
| 2026-05-20 | MYGN | 3.81 | -175.6 | - | 0.06 |
| 2026-05-21 | MYGN | 3.91 | -175.6 | - | 0.05 |
| 2026-05-22 | MYGN | 3.82 | -220.0 | - | 0.05 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-23 | MYGN | 2.32 | -5.64 | 10.06 |
| 2026-04-24 | MYGN | 2.32 | -5.64 | 10.06 |
| 2026-04-27 | MYGN | 2.32 | -5.32 | 9.46 |
| 2026-04-28 | MYGN | 2.32 | -5.32 | 9.46 |
| 2026-04-29 | MYGN | 2.32 | -5.32 | 9.46 |
| 2026-04-30 | MYGN | 2.32 | -5.32 | 9.46 |
| 2026-05-01 | MYGN | 2.32 | -5.32 | 9.46 |
| 2026-05-04 | MYGN | 2.32 | -5.40 | 9.46 |
| 2026-05-05 | MYGN | 2.32 | -5.40 | 9.46 |
| 2026-05-06 | MYGN | 2.32 | -5.40 | 9.46 |
| 2026-05-07 | MYGN | 2.32 | -5.40 | 9.46 |
| 2026-05-08 | MYGN | 2.32 | -5.40 | 9.45 |
| 2026-05-11 | MYGN | 2.31 | -5.90 | 9.36 |
| 2026-05-12 | MYGN | 2.31 | -5.90 | 8.95 |
| 2026-05-13 | MYGN | 2.31 | -5.90 | 8.95 |
| 2026-05-14 | MYGN | 2.31 | -5.90 | 8.95 |
| 2026-05-15 | MYGN | 2.44 | -5.90 | 8.95 |
| 2026-05-18 | MYGN | 2.44 | -10.01 | 8.90 |
| 2026-05-19 | MYGN | 2.65 | -10.01 | 8.90 |
| 2026-05-20 | MYGN | 2.65 | -10.01 | 8.90 |
| 2026-05-21 | MYGN | 2.65 | -10.01 | 8.91 |
| 2026-05-22 | MYGN | 2.59 | -10.01 | 8.91 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.16
Avg. EPS Est. Current Quarter
-0.06
Avg. EPS Est. Next Quarter
0.07
Insider Transactions
2.59
Institutional Transactions
-10.01
Beta
1.77
Average Sales Estimate Current Quarter
206
Average Sales Estimate Next Quarter
225
Fair Value
Quality Score
37
Growth Score
37
Sentiment Score
46
Actual DrawDown %
89.7
Max Drawdown 5-Year %
-90.3
Target Price
6.38
P/E
Forward P/E
23.87
PEG
0.35
P/S
0.44
P/B
1.07
P/Free Cash Flow
EPS
-4.32
Average EPS Est. Cur. Y
0.05
EPS Next Y. (Est.)
0.16
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-48.24
Relative Volume
0.53
Return on Equity vs Sector %
-145.6
Return on Equity vs Industry %
-129.4
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.01
EBIT Estimation
◆
MYGN
Healthcare
$3.82
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
39.7
Range 1M
17.9%
Sup Dist
1.6%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
3.7%
EPS NY
157.1%
52W%
5.4%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+52.4% upside
Upside
+52.4%
Quality
37
Myriad Genetics, Inc.Sector: Healthcare
Industry: Diagnostics & Research
Employees: 2700
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
MYGN
Latest News
—
Caricamento notizie per MYGN…
stock quote shares MYGN – Myriad Genetics, Inc. Stock Price stock today
news today MYGN – Myriad Genetics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MYGN – Myriad Genetics, Inc. yahoo finance google finance
stock history MYGN – Myriad Genetics, Inc. invest stock market
stock prices MYGN premarket after hours
ticker MYGN fair value insiders trading